China Universal Asset Management Company’s Zentalis Pharmaceuticals ZNTL Stock Holding History

China Universal Asset Management Company’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-13,676	Closed	-$50.3K	–	526
2024 Q3	$50.3K	Buy	13,676 +5,333	+64%	+$19.4K	0.01%	386
2024 Q2	$34.1K	Sell	8,343 -5,291	-39%	-$59.1K	﹤0.01%	377
2024 Q1	$215K	Buy	13,634 +5,446	+67%	+$74.9K	0.03%	280
2023 Q4	$124K	Buy	8,188 +6,379	+353%	+$93.1K	0.02%	254
2023 Q3	$36.3K	Buy	1,809 +1,030	+132%	+$26.1K	0.01%	251
2023 Q2	$22K	Buy	779 +6	+0.8%	+$144	0.01%	257
2023 Q1	$13.3K	Buy	773 +194	+34%	+$3.93K	﹤0.01%	260
2022 Q4	$11.7K	Buy	579 +45	+8%	+$968	﹤0.01%	213
2022 Q3	$12K	Buy	+534	New	+$14.6K	0.01%	189

Other funds holding ZNTL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

China Universal Asset Management Company's ZNTL Position: Q4 2024 in Review

China Universal Asset Management Company sold out of Zentalis Pharmaceuticals (ZNTL) in Q4 2024, closing a stake of 13,676 shares — an estimated $50.3K sold.

China Universal Asset Management Company first reported a position in ZNTL in Q3 2022 and held it in 9 quarters. The position peaked at $215K in Q1 2024. 142 funds tracked by Wall St. Rank hold ZNTL as of Q4 2024.

China Universal Asset Management Company reported no remaining Zentalis Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
China Universal Asset Management Company sold 13,676 Zentalis Pharmaceuticals shares in Q4 2024, an estimated $50.3K.
China Universal Asset Management Company first reported a position in Zentalis Pharmaceuticals in Q3 2022 and held it in 9 quarters.
China Universal Asset Management Company's Zentalis Pharmaceuticals position peaked at $215K in Q1 2024.
142 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q4 2024.

Based on China Universal Asset Management Company's 13F filing for Q4 2024, filed 24 Jan 2025.